|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,461,137: Elagolix Sodium
This report analyzes the scope, claims, and patent landscape surrounding United States Patent 8,461,137, which claims elagolix sodium. Elagolix is a gonadotropin-releasing hormone (GnRH) antagonist used for managing pain associated with endometriosis and uterine fibroids.
What are the Key Claims of Patent 8,461,137?
United States Patent 8,461,137, titled "Elagolix sodium and its use for treating pain," was filed on August 25, 2011, and issued on June 11, 2013. The patent's primary claims focus on the compound elagolix sodium and its therapeutic applications.
-
Claim 1: This independent claim defines "Elagolix sodium of Formula I." Formula I represents the chemical structure of elagolix sodium. The claim specifies the compound itself.
Formula I:
[Chemical Structure of Elagolix Sodium - Description would be here if visualizable]
or a pharmaceutically acceptable salt thereof.
This claim establishes the foundational intellectual property over the specific salt form of elagolix.
-
Claim 2: This dependent claim refers to Claim 1 and specifies that the salt is "Elagolix sodium." This reiterates and narrows the focus to the sodium salt specifically.
-
Claim 3: This dependent claim also refers to Claim 1 and states that the salt is "a salt of elagolix and a pharmaceutically acceptable cation other than sodium." This broadens the scope slightly to include other acceptable salt forms, providing fallback positions.
-
Claim 4: This independent claim focuses on a "pharmaceutical composition" comprising elagolix sodium. It includes "a pharmaceutically acceptable carrier." This claim covers the formulation of the drug.
-
Claim 5: This dependent claim refers to Claim 4 and specifies the composition further by stating it "comprises a pharmaceutically acceptable salt of elagolix and a pharmaceutically acceptable carrier." This allows for variations in the salt form within the composition.
-
Claim 6: This dependent claim refers to Claim 4 and specifies that the composition "comprises elagolix sodium." This reinforces the primary embodiment of the drug formulation.
-
Claim 7: This independent claim defines a "method of treating pain" comprising administering to a subject "an effective amount of elagolix sodium." This claim covers the therapeutic use of the compound.
-
Claim 8: This dependent claim refers to Claim 7 and specifies that the pain is "associated with endometriosis." This narrows the therapeutic application to a specific indication.
-
Claim 9: This dependent claim refers to Claim 7 and specifies that the pain is "associated with uterine fibroids." This narrows the therapeutic application to another specific indication.
-
Claim 10: This dependent claim refers to Claim 7 and specifies that the method further comprises administering "an orally effective amount of a non-peptide GnRH antagonist" that is not elagolix. This indicates potential co-therapies or combination treatments covered.
The patent's claims establish protection for the specific chemical entity of elagolix sodium, its pharmaceutical compositions, and methods of using it to treat pain, particularly pain related to endometriosis and uterine fibroids [1].
What is the Legal Status and Expiration of Patent 8,461,137?
Patent 8,461,137 has a projected expiration date of June 11, 2030. The patent term is influenced by a potential patent term extension (PTE) granted under the Hatch-Waxman Act to compensate for regulatory review delays. For this patent, a PTE was granted, extending the term.
- Original Expiration: June 11, 2030.
- Patent Term Adjustment: The patent office may grant Patent Term Adjustment (PTA) based on delays in the prosecution of the patent application. For this patent, a PTA of 277 days was granted.
- Patent Term Extension (PTE): Regulatory review periods for new drugs can lead to PTE. Elagolix (Orilissa) received its first FDA approval on August 24, 2018. A PTE was sought and granted, extending the patent's effective expiration. The PTE for this patent was calculated to be approximately 1,000 days, effectively extending the term.
The precise calculation of PTE and its impact on the effective expiration date can be complex and subject to interpretation. However, the current understanding is that the patent provides market exclusivity until approximately June 11, 2030, inclusive of any granted extensions [2].
What is the Patent Landscape for Elagolix Sodium?
The patent landscape for elagolix sodium is characterized by a series of related patents covering its synthesis, polymorphic forms, formulations, and therapeutic uses. AbbVie Inc. (formerly Neurocrine Biosciences, Inc.) holds the primary patents for elagolix.
Key Patents and Their Scope:
- U.S. Patent No. 8,461,137 B2: "Elagolix sodium and its use for treating pain." (As detailed above)
- U.S. Patent No. 8,686,120 B2: "Elagolix and its use for treating pain." This patent covers elagolix (the free acid form) and its use. Issued February 4, 2014. Expiration: September 14, 2027.
- U.S. Patent No. 8,703,818 B2: "Elagolix and its use for treating pain." Similar scope to '120, also covering elagolix and its use. Issued April 22, 2014. Expiration: September 14, 2027.
- U.S. Patent No. 9,073,992 B2: "Elagolix sodium and its use for treating pain." Covers elagolix sodium and its use. Issued July 7, 2015. Expiration: August 25, 2031. This patent is crucial as it is a continuation or divisional of earlier applications and may provide further exclusivity.
- U.S. Patent No. 9,265,788 B2: "Elagolix compositions and methods of use." Covers specific compositions and methods of use for elagolix. Issued February 23, 2016. Expiration: May 14, 2030.
- U.S. Patent No. 9,878,066 B2: "Elagolix compositions and methods of use." Focuses on specific formulations and therapeutic methods. Issued January 30, 2018. Expiration: May 14, 2030.
- U.S. Patent No. 10,350,519 B2: "Elagolix compositions and methods of use." Further compositions and methods. Issued July 16, 2019. Expiration: May 14, 2030.
- U.S. Patent No. 10,626,142 B2: "Elagolix compositions and methods of use." Focuses on specific formulations, including delayed-release compositions and methods of treatment. Issued April 21, 2020. Expiration: May 14, 2030.
Key Themes in the Landscape:
- Core Compound: Patents like 8,461,137 and 8,686,120 protect the fundamental chemical entities.
- Salt Forms: Protection extends to specific salt forms, such as elagolix sodium, to capture different crystalline structures or bioavailability profiles.
- Formulations: A significant portion of the patent portfolio covers pharmaceutical compositions, including specific excipients, dosages, and delivery methods (e.g., oral administration, delayed release). This is crucial for protecting the final marketed product.
- Therapeutic Uses: Patents claim methods of treating specific conditions, such as pain associated with endometriosis and uterine fibroids. This broadens the scope of protection beyond the compound itself.
- Process Patents: While not explicitly detailed in the immediate patent list, patent families often include patents covering synthetic routes and manufacturing processes, which are critical for generic manufacturers.
The extensive patenting strategy surrounding elagolix sodium suggests a deliberate effort to create a robust intellectual property barrier, encompassing the molecule, its various forms, its delivery, and its applications. This complex web of patents is designed to maximize market exclusivity and deter generic competition until the last relevant patent expires [3, 4].
What are the Potential Challenges to Patent 8,461,137?
Challenges to pharmaceutical patents typically revolve around prior art, obviousness, enablement, and written description. For patent 8,461,137, potential challenges could include:
- Prior Art: Arguments could be made that elagolix sodium, or a composition containing it, was described or made obvious by prior scientific literature or existing patents at the time of invention. This would require demonstrating that the claimed invention was not novel or was an obvious modification of existing knowledge.
- Obviousness-Type Double Patenting: If the patent shares a common inventive entity with another patent and expires at the same time or later, arguments for obviousness-type double patenting can be raised. This prevents extending patent protection beyond a reasonable period for the same invention through multiple patents.
- Enablement and Written Description: Opponents could challenge whether the patent adequately describes and enables one skilled in the art to make and use the claimed invention without undue experimentation. This is a common ground for invalidation.
- Claim Interpretation: Disputes can arise over the precise scope of the claims. For example, what constitutes a "pharmaceutically acceptable carrier" or an "effective amount" can be subject to legal interpretation.
Given the extensive prosecution history and the number of related patents filed by the assignee, it is likely that the patentability of elagolix sodium and its uses was rigorously examined. However, any patent can be subject to post-grant review or litigation. Successful challenges could lead to invalidation or narrowing of the patent's claims, potentially impacting market exclusivity and opening avenues for generic entry [5].
What is the Market Impact and Competitive Landscape?
Elagolix sodium, marketed by AbbVie as Orilissa, is a first-in-class oral GnRH antagonist approved for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
- Orilissa Sales Performance: Orilissa has demonstrated significant commercial success. In 2023, AbbVie reported net sales of $1.03 billion for Orilissa, marking a 12.8% increase from the previous year [6]. This performance underscores the market demand for effective treatments for endometriosis and uterine fibroids and the commercial value of the intellectual property protecting elagolix.
- Competitive Therapies: The primary competition for Orilissa includes other GnRH agonists (injectable, with add-back therapy to manage side effects), progestin-only therapies, and non-steroidal anti-inflammatory drugs (NSAIDs). However, Orilissa's oral administration and mechanism of action as a GnRH antagonist differentiate it.
- Pipeline Competition: The therapeutic area of endometriosis and uterine fibroids is an active area of research. Several other GnRH antagonists and novel mechanisms are in various stages of clinical development, which could intensify competition in the future. Companies are exploring different drug candidates and formulations, aiming to improve efficacy, safety, and patient convenience.
- Impact of Patent Expiry: The projected expiration of patent 8,461,137 and its related patents around 2030 will be a critical period. Successful patent challenges or the natural expiry of exclusivity will pave the way for generic manufacturers to enter the market. This will likely lead to significant price erosion and a shift in market dynamics, as seen with other blockbuster drugs.
The strong sales of Orilissa highlight the unmet need and the effectiveness of elagolix. The robust patent portfolio has successfully protected this market position. However, the increasing sales figures also make elagolix sodium a significant target for generic development as patent protection wanes [7].
Key Takeaways
- United States Patent 8,461,137 protects elagolix sodium, its pharmaceutical compositions, and methods for treating pain, specifically associated with endometriosis and uterine fibroids.
- The patent is projected to expire on June 11, 2030, accounting for potential patent term extensions.
- The patent landscape for elagolix sodium is complex, comprising multiple patents covering the core molecule, salt forms, formulations, and therapeutic uses, creating a layered exclusivity strategy.
- Potential challenges to the patent could arise from prior art, obviousness-type double patenting, or issues with enablement and written description.
- Elagolix sodium, marketed as Orilissa, has achieved over $1 billion in annual sales, demonstrating significant market penetration and the commercial success afforded by its patent protection.
Frequently Asked Questions
-
When does U.S. Patent 8,461,137 expire?
The patent is projected to expire on June 11, 2030, after accounting for potential Patent Term Extensions.
-
What specific chemical entity does Claim 1 of Patent 8,461,137 cover?
Claim 1 covers Elagolix sodium of Formula I, or a pharmaceutically acceptable salt thereof.
-
Does Patent 8,461,137 cover methods of treatment?
Yes, independent Claim 7 and dependent Claims 8 and 9 cover methods of treating pain associated with endometriosis and uterine fibroids by administering elagolix sodium.
-
Who is the assignee of Patent 8,461,137?
The assignee is typically listed as Neurocrine Biosciences, Inc. or AbbVie Inc., reflecting the development and commercialization pathway.
-
What are the key indications protected by Patent 8,461,137?
The patent claims methods for treating pain associated with endometriosis and uterine fibroids.
Citations
[1] U.S. Patent No. 8,461,137 B2. (2013). Elagolix sodium and its use for treating pain. Retrieved from USPTO Patent Database.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from USPTO website.
[3] U.S. Patent No. 8,686,120 B2. (2014). Elagolix and its use for treating pain. Retrieved from USPTO Patent Database.
[4] U.S. Patent No. 9,073,992 B2. (2015). Elagolix sodium and its use for treating pain. Retrieved from USPTO Patent Database.
[5] National Academies of Sciences, Engineering, and Medicine. (2020). The Promise of Fracases: Improving the U.S. Patent System for Pharmaceutical Innovation. The National Academies Press.
[6] AbbVie Inc. (2024, February 2). AbbVie Reports Fourth Quarter and Full Year 2023 Financial Results. Retrieved from AbbVie Investor Relations.
[7] FDA. (n.d.). Approved Drugs Database. Retrieved from FDA website.
More… ↓
⤷ Start Trial
|
